Ken Griffin Regeneron Pharmaceuticals, Inc. Transaction History

Citadel Advisors LLC

$509 Billion
Q1 2024

A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Regeneron Pharmaceuticals, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 122,900 shares of REGN stock, worth $128 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares

122,900

Previous 241,400 49.09%

Holding current value

$128 Million

Previous $212 Million 44.21%

% of portfolio

0.02%

Previous 0.04%

26 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$902.69 - $993.35 $186 Million - $205 Million	-206,013 Reduced 72.39%	78,578 $75.6 Million
Q4 2023 Feb 14, 2024	BUY	$775.18 - $881.7 $171 Million - $194 Million	220,135 Added 341.53%	284,591 $250 Million
Q3 2023 Nov 14, 2023	BUY	$692.45 - $844.37 $17.1 Million - $20.9 Million	24,730 Added 62.25%	64,456 $53 Million
Q2 2023 Aug 14, 2023	SELL	$700.03 - $830.35 $176 Million - $209 Million	-251,520 Reduced 86.36%	39,726 $28.5 Million
Q1 2023 May 15, 2023	BUY	$680.49 - $826.97 $146 Million - $177 Million	214,170 Added 277.87%	291,246 $239 Million

Q4 2022 Feb 14, 2023	BUY	$705.89 - $766.39 $41.6 Million - $45.2 Million	58,926 Added 324.66%	77,076 $55.6 Million
Q3 2022 Nov 14, 2022	BUY	$573.97 - $724.32 $5.14 Million - $6.49 Million	8,956 Added 97.41%	18,150 $12.5 Million
Q2 2022 Aug 15, 2022	SELL	$548.35 - $738.84 $4.83 Million - $6.5 Million	-8,803 Reduced 48.91%	9,194 $5.44 Million
Q1 2022 May 16, 2022	SELL	$595.12 - $698.43 $48.8 Million - $57.2 Million	-81,923 Reduced 81.99%	17,997 $12.6 Million
Q4 2021 Feb 14, 2022	SELL	$543.48 - $670.97 $5.22 Million - $6.44 Million	-9,603 Reduced 8.77%	99,920 $63.1 Million
Q3 2021 Nov 15, 2021	BUY	$574.03 - $680.96 $29.7 Million - $35.2 Million	51,755 Added 89.59%	109,523 $66.3 Million
Q2 2021 Aug 16, 2021	BUY	$472.8 - $558.54 $18 Million - $21.3 Million	38,085 Added 193.49%	57,768 $32.3 Million
Q1 2021 May 17, 2021	SELL	$446.73 - $548.2 $8.64 Million - $10.6 Million	-19,338 Reduced 49.56%	19,683 $9.31 Million
Q4 2020 Feb 16, 2021	BUY	$478.3 - $607.98 $11 Million - $14 Million	23,016 Added 143.81%	39,021 $18.9 Million
Q3 2020 Nov 16, 2020	SELL	$544.75 - $658.21 $4.09 Million - $4.94 Million	-7,509 Reduced 31.93%	16,005 $8.96 Million
Q1 2020 May 15, 2020	SELL	$336.18 - $494.43 $125 Million - $184 Million	-372,365 Reduced 94.06%	23,514 $11.5 Million
Q4 2019 Feb 14, 2020	BUY	$274.13 - $376.51 $65.9 Million - $90.6 Million	240,518 Added 154.81%	395,879 $149 Million
Q3 2019 Nov 14, 2019	SELL	$273.46 - $318.39 $114 Million - $133 Million	-417,518 Reduced 72.88%	155,361 $43.1 Million
Q2 2019 Aug 14, 2019	BUY	$299.6 - $414.82 $118 Million - $164 Million	394,489 Added 221.14%	572,879 $179 Million
Q1 2019 May 15, 2019	BUY	$372.08 - $439.57 $40.9 Million - $48.3 Million	109,848 Added 160.26%	178,390 $0
Q4 2018 Feb 14, 2019	BUY	$335.82 - $403.04 $8.57 Million - $10.3 Million	25,509 Added 59.28%	68,542 $25.6 Million
Q3 2018 Nov 13, 2018	SELL	$351.14 - $408.51 $4.54 Million - $5.29 Million	-12,943 Reduced 23.12%	43,033 $0
Q2 2018 Aug 10, 2018	BUY	$284.6 - $344.99 $7.61 Million - $9.23 Million	26,745 Added 91.5%	55,976 $0
Q1 2018 May 11, 2018	SELL	$315.82 - $393.78 $49.2 Million - $61.4 Million	-155,855 Reduced 84.21%	29,231 $10.1 Million
Q4 2017 Feb 09, 2018	BUY	$358.63 - $469.95 $63.6 Million - $83.4 Million	177,431 Added 2317.84%	185,086 $69.6 Million
Q3 2017 Nov 09, 2017	BUY	$431.38 - $504.0 $3.3 Million - $3.86 Million	7,655	7,655 $3.42 Million

Others Institutions Holding REGN

# of Institutions

1,426

Shares Held

82.1M

Call Options Held

835K

Put Options Held

1.46M

View Full List

About REGENERON PHARMACEUTICALS, INC.

Ticker REGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 107,190,000
Market Cap $112B
Description
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macula...

More about REGN

Track Ken Griffin's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Account